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Abstract 
Background 
Visual hallucinations (VHs) are common in Parkinson’s disease (PD), with prevalence ranging from 
27-50% in cross-sectional cohorts of patients with well established disease. However, minor 
hallucinations may occur earlier in the disease process than has been previously reported and so we 
sought to categorise VHs in a cohort of newly diagnosed PD patients and their relationship to other 
clinical features. 
Methods 
Newly diagnosed PD participants (n=154) were recruited as part of the Incidence of Cognitive 
Impairment in Cohorts with Longitudinal Evaluation in PD (ICICLE-PD) study. Participants completed 
the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS III), Montreal 
Cognitive Assessment (MoCA) and Parkinson’s Disease Questionnaire (PDQ-39) to assess motor 
severity, cognition and quality of life (QoL), respectively. VHs were classified using the North East 
Visual Hallucinations Inventory. Hierarchical regression was used to build predictive models of motor 
severity, QoL and cognition. 
Results  
22% (n=34) of participants experienced recurrent VHs with minor VHs being most frequently 
reported (64.7% of hallucinators). Complex VHs were present in 32.4% of hallucinating participants. 
Linear regression showed VHs predicted poorer PDQ-39 and MoCA scores (β=0.201, p=0.006 and β=-
0.167, p=0.01, respectively) but not motor severity (p>0.05).  
Conclusions 
 
 
3 
 
Over a fifth of people with newly diagnosed PD reported recurrent VHs; minor hallucinations were 
the most common, although a small proportion reported complex VHs. Recurrent VHs were found to 
be a significant independent predictor of cognitive function and QoL but not motor severity. Our 
findings highlight the importance of screening for VHs at diagnosis. 
Introduction 
Visual hallucinations (VHs) are common in Parkinson’s disease (PD) with prevalence rates ranging 
from 27-50% in patients with well-established disease [1]. Their presence can be distressing and are 
associated with poorer quality of life (QoL) in both patients [2] and caregivers [3], as well as with 
motor severity [1, 4, 5] and cognitive impairment [6] with progression to dementia (PDD). Risk 
factors associated with VHs in PD are disease severity and depression [1, 4, 7], although this 
association appears to be less pronounced in early PD participants with some such studies finding no 
association at all [8, 9].  
Fully formed complex VHs are usually seen at later stages of PD and in PDD [10]. In contrast, minor 
hallucinations, which have previously been defined as a feeling of presence or passing of an entity 
[1] and typically last a few seconds, have been said to occur in as many as 42% of PD patients, 
including those in early stage disease [9]. Furthermore, minor VHs have been found to be less 
malignant that complex VHs in terms of associated risk of cognitive impairment [11], but this is 
unresolved and may be a more significant predictor of cognitive problems in patients in early stage 
disease. We therefore sought to address this question of the characteristics of hallucinations in 
newly diagnosed incident PD and establish their relationship with motor severity, cognitive function 
and QoL.  
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Methods 
Participants 
Subjects participated in the Incidence of Cognitive Impairment in Cohorts with Longitudinal 
Evaluation in PD (ICICLE-PD) study [12]. Newly diagnosed idiopathic PD patients from Newcastle 
upon Tyne and Gateshead (UK) were invited to participate between June 2009 and December 2011 
from community and outpatient clinics. Patients were diagnosed by a movement disorder specialist 
and met Queen’s Square Brain Bank criteria for idiopathic PD [13]. Patients were excluded if they 
had significant cognitive impairment defined as a Mini Mental State Examination (MMSE) score <24 
or a diagnosis of dementia [14]. Patients with insufficient English to be assessed, PD diagnosis before 
the onset of the study, drug-induced parkinsonism, vascular parkinsonism and atypical forms of 
parkinsonism such as progressive supranuclear palsy, multiple system atrophy, or corticobasal 
degeneration were also excluded. This study was approved by the Newcastle and North Tyneside 
Research Ethics Committee. All subjects provided written informed consent. 
Assessments  
Participants completed a schedule of assessments. Participants were assessed when “on” their 
normal anti-PD medication. Demographic data included age, gender, disease duration and number 
of years in education. PD medications were recorded and levodopa equivalent daily dose (LEDD) was 
calculated [15]. Disease severity was assessed using the Movement Disorders Society Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS) part II and III  [16] and Hoehn and Yahr stage [17]. 
Motor phenotypes were defined using the MDS-UPDRS scale as Postural Instability/Gait difficulty 
(PIGD), Tremor Dominant (TD) or Indeterminate phenotype [18].  
The Geriatric Depression Scale (GDS-15) [19] was used to assess depression. Excessive daytime 
sleepiness was assessed using the Epworth Sleepiness Scale (ESS) [20]; the Pittsburgh Sleep Quality 
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Index (PSQI) [21] was used to assess sleep quality and disturbance. Quality of life was assessed using 
the Parkinson’s Disease Questionnaire (PDQ-39, with higher scores representing poorer QoL) [22]. 
The MMSE [23] and Montreal Cognitive Assessment (MoCA) [24] were used to assess global 
cognition. We used modified mild cognitive impairment (PD-MCI) criteria to determine whether a 
patient had MCI – namely scores that were 1.5 standard deviations (SD) below normative means [12, 
25] in two tests, either within one cognitive domain or in two different domains, as described 
previously [26].  
An assessment of VHs was conducted using the North East Visual Hallucination Inventory (NEVHI) 
[27]. This semi-structured interview identifies and assesses VHs by category (complex, illusions, 
simple and minor, Supplementary Table 1), and by frequency. For the purposes of this study, floaters 
and hallucinations occurring in the context of a migraine were excluded and analyses focused on 
recurrent hallucinations in the last month. Recurrent hallucinations were defined as more than one 
separate episode of hallucination, as per the NEVHI. These criteria was used to classify VHs in the 
analysis to exclude those who had experienced hallucinations in a non PD context such as, for 
example, from an episode of delirium. 
Statistical analysis 
Statistical analyses were performed using SPSS (Version 21.0. Armonk, NY: IBM Corp). The normality 
distribution of the data was assessed using the Kolmogorov-Smirnov test and visual histograms. 
Differences between two groups were assessed using either independent t-tests or Mann–Whitney 
U tests as appropriate. Comparisons between more than two groups were conducted with Kruskal-
Wallis tests. Chi-squared tests were used to compare differences between categorical variables. 
Significance was set at p<0.05 for all analyses. Bonferroni’s correction was applied for multiple 
comparisons.  
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Hierarchical regression was used to determine predictors of QoL, cognition and motor severity. 
Backwards stepwise regression was used and non-significant predictors were excluded to produce a 
basic model for each dependent variable. Predictors of PDQ-39 scores included GDS-15 scores, 
gender, years of education, age and MDS-UPDRS part III scores [28, 29]. Predictors of cognition using 
MoCA scores included in the initial model comprised ESS scores, MDS-UPDRS part III scores, age and 
years of education [12]. Predictors of MDS-UPDRS part III scores included in the initial model 
included gender, GDS-15 scores, PD-MCI and age [30]. To determine whether VHs were an 
independent predictor of each outcome, occurrence of recurrent VHs or not was subsequently 
added as a binary variable to the basic model. 
Results 
Of the 158 individuals enrolled [31], 154 participants completed the NEVHI and were therefore 
included in this study (Table 1). Application of the NEVHI identified 38.3% (n=59) of the participants 
as having any previous VHs.  Of these, 22.1% (n=34) reported having recurrent VHs in the last month. 
Of the participants reporting recurrent VHs, 41.2% (n=14) reported more than one type of VH. The 
most frequently reported classification of VHs were minor hallucinations (64.7%, n=22). 38.2% 
(n=13) of participants with recurrent VHs reported recurrent simple VHs and 20.6% (n=7) reported 
recurrent illusions. Eleven participants (32.4%) reported recurrent complex VHs such as animals and 
people, including familiar and deceased individuals. 
Clinical features of patients with and without VHs 
The clinical characteristics of those patients with and without recurrent VHs were compared (Table 
2). There was no difference in age, but those with recurrent VHs were more likely to be male. 
Participants with recurrent VHs had significantly poorer QoL, (PDQ-39 26.7 ± 17.0 vs. 16.4 ± 12.7, 
respectively, p=0.001), higher daytime somnolence scores (ESS 8.8 ± 5.0 vs. 5.4 ± 4.1, respectively, 
p<0.001) and more depressive symptoms (GDS-15 3.9 ± 3.1 vs. 2.5 ± 2.3, respectively, p=0.015) 
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compared to those without VHs.  Lower global cognition scores were found in participants with VHs 
compared to those without using both the MoCA and the MMSE scores. There was no difference 
between those experiencing and not experiencing recurrent VHs regarding the proportion of 
participants on dopaminergic medication, although the total number of drug-naïve participants was 
low (n=19), reflective of clinical practice (Table 2).  
A trend towards a difference in motor phenotypes was found between those with and without 
recurrent VHs (Table 2, p=0.063). Within the recurrent VH group, there was a significantly higher 
proportion of participants identified as PIGD compared to indeterminate or tremor dominant 
phenotypes (61.8% vs. 14.7% vs. 23.5%, respectively; χ2=21.05, p<0.001). 
Participants with recurrent VHs were categorised according to the most severe classification of 
hallucinations reported to create distinct groups of participants with VHs, such that complex VHs > 
illusions > simple VHs > minor VHs (Table 3). No significant differences in any clinical characteristic 
were found between groups. Post hoc analysis did not reveal significant differences when using two 
group comparisons after Bonferroni corrections were applied (p<0.008). 
The effects of VH on quality of life, cognition and motor severity 
We next investigated whether recurrent VHs were predictive of clinical features. Backwards 
stepwise linear regression was used to determine predictors of PDQ-39, MDS-UPDRS part III and 
MoCA scores. Occurrence of VHs were then added to the model. Covariates are listed in Table 4. 
Recurrent VHs were a significant predictor of poorer QoL scores, accounting for 2.3% of the variance 
(ΔR2 = 0.023, p=0.006) and poorer cognition, accounting for 3.7% of the variance (ΔR2 = 0.037, 
p<0.001, Table 4). However, recurrent VHs were not a significant predictor of MDS-UPDRS part III 
scores (p>0.05). 
 
 
8 
 
Discussion 
This study found recurrent VHs were reported in 22% of newly diagnosed PD participants. The most 
prevalent form was minor hallucinations, although 32% reported complex VHs, and their presence 
was associated with both poorer cognition and QoL.  
Our finding of over one in five incident PD patients reporting VH is similar to that reported by 
Pagonabarraga et al. [9], where they found that 24% of drug-naïve early PD patients experienced 
VHs more than once per week, albeit in a smaller sample (n=50). Our study also found, in line with 
this study of Pagonabarraga et al, that minor VHs were the most frequently reported VH, occurring 
in 65% of recurrent hallucinators. However we also uniquely found that 32% of recurrent 
hallucinators reported complex VHs, which is surprising given their association with later stages of 
PD and PDD [6] and the fact that we found no differences in the clinical characteristics of patients 
with these different forms of VHs. This may have been due to the small numbers in each VH 
classification group.  
However, we did find that recurrent VHs were significantly associated with worse global cognition 
scores using the MoCA, independent of age and years of education - although what happens over 
time is still being investigated as we follow up this cohort. In particular, understanding the 
relationship over time between cognition and VHs could be useful in identifying those at risk of 
developing PDD in the future  [32, 33].  
Consistent with previous findings in newly diagnosed patients [9], there was no significant difference 
in motor phenotype classification or in motor severity between participant with and without 
recurrent VHs. It has been previously reported that VHs are found in patients with greater motor 
severity of disease [1, 7], although this was generally in participants with more advanced PD than in 
our cohort. The participants in our study had a mean disease duration of six months and were largely 
Hoehn and Yahr stage one or two.  
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We found that QoL was significantly poorer in participants reporting VHs, in line with earlier studies 
[2, 34]. It has previously been suggested that reduced QoL in hallucinators may be due to depression 
[4] and reduced independence through nursing home placement [35]. However, our participants 
were newly diagnosed in early stages of PD, with none living in nursing or residential care and only a 
few meeting a diagnostic criteria for depression, as measured by the GDS-15. 
The main strengths of this study include a large well characterised representative incident cohort of 
patients, which by virtue of being a longitudinal study, means that misdiagnosis rates are minimised. 
The majority of participants in the present study were on dopaminergic medication (87.7%) at the 
time of recruitment (even though the mean disease duration was only 6 months) which is 
representative of patients in real life clinical practice. Limitations included the small subgroup sizes, 
which limited statistical power to detect subtle differences between groups, as well as our analysis 
being cross-sectional, which means we cannot draw conclusions regarding the relationship between 
VHs and disease progression or cognitive decline. Finally, this study used global measures of 
cognition, which may have missed important findings regarding which specific cognitive modalities 
are associated with VHs early in PD.  
In summary, we have found that VHs are common even in newly diagnosed PD patients, with minor 
hallucinations being the most frequently reported. These results highlight the importance of 
screening for VHs in early PD. Recurrent VHs in early PD were associated with poorer global 
cognition and QoL, but not with motor severity and as such may be an early harbinger of the 
development of PD dementia.  However, the longitudinal follow up of our cohort is required to 
answer this question.  
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Table 1. Demographic and clinical data 
 Participant 
characteristics 
(n=154) 
 n (%) 
Sex: male 100 (64.9) 
Dopaminergic medication 135 (87.7) 
PD-MCI  68 (41.2) 
 Mean ± SD 
Age (years) 66.4 ± 10.4 
Years of education 12.8 ± 3.8 
Duration of PD (months) 6.0 ± 4.6 
LEDD (mg/ day) 178.1 ± 148.2 
Hoehn and Yahr 2.0 ± 0.7 
MoCA 25.2 ± 3.7 
MMSE 28.6 ± 13.1 
GDS-15 2.8 ± 2.5 
MDS-UPDRS part III 26.9 ± 12.1 
ESS 6.2 ± 4.5 
PDQ-39 18.7 ± 14.4 
PSQI 6.3 ± 3.9 
MoCA = Montreal Cognitive Assessment, MMSE = Mini-Mental State Examination, MDS-UPDRS = Movement Disorder Society - Unified 
Parkinson's disease rating scale, LEDD = Levodopa equivalent daily dose, GDS-15 = 15 item Geriatric Depression Scale , PSQI - Pittsburgh 
Sleep Quality Index global score , ESS = Epworth Sleepiness Scale , PDQ-39 = Parkinson’s Disease Questionnaire summary index. 
N = 15 did not complete the MoCA 
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Table 2: Clinical characteristics of newly diagnosed participants with Parkinson’s disease with and 
without recurrent visual hallucinations 
 Participants with 
recurrent visual 
hallucinations 
(n=34)  
Participants without 
recurrent visual 
hallucinations 
(n=120)  
t/χ2/Z  
 
P 
Age (years) 65.7 ± 9.2 66.6 ± 10.7 0.39 0.696 t 
Sex: male n(%)  
PD-MCI n(%) 
27 (79.4) 
16 (47.1) 
73 (60.8) 
49 (40.8) 
4.02 
0.42 
0.045 x 
0.516x 
Education (years) 12.2 ± 3.6 12.9 ± 3.9 -1.28 0.199 
Disease duration (months) 6.2 ± 4.5 6.0 ± 4.6 -0.49 0.623 
Motor Phenotype n (%) 
PIGD 
Indeterminate 
Tremor dominant 
 
21 (61.8) 
5 (14.7) 
8 (23.5) 
 
48 (40.0) 
20 (16.7) 
52 (43.3) 
5.53 0.063x 
MoCA 23.8 ± 3.9 25.5 ± 3.5 -2.24 0.025 
MMSE 28.2 ± 1.4 28.8 ± 1.3 -2.26 0.024 
MDS-UPDRS Part II 12.3 ± 5.4 10.4 ± 5.8 -1.75 0.081 
MDS-UPDRS Part III  28.3 ± 12.0 26.5 ± 12.1 -0.74 0.459 t 
Hoehn and Yahr 2.0 ± 0.7 2.0 ± 0.7 -0.24 0.815 
LEDD (mg/day) 186.9 ± 149.1 175.5 ± 148.4 -0.70 0.485 
Receiving dopaminergic 
therapy n (%) 
 
29 (85.3) 
 
106 (88.3) 
 
0.23 
 
0.634 
GDS-15 3.9 ± 3.1 2.5 ± 2.3 -2.43 0.015 
PSQI  7.2 ± 4.7 6.0 ± 3.7 -1.13 0.260 
ESS 8.8 ± 5.0 5.4 ± 4.1 -3.52 <0.001 
PDQ-39 26.7 ± 17.0 16.4 ± 12.7 -3.28 0.001 
Data presented as mean ± SD unless otherwise stated X= chi squared, t= independent samples t test, remainder of tests were Mann–
Whitney U test. Significant results highlighted in bold (p<0.05) 
PD-MCI = Mild Cognitive Impairment at 1.5SD, PIGD = Postural Instability Gait Difficulty, MoCA = Montreal Cognitive Assessment, MMSE = 
Mini-Mental State Examination, MDS-UPDRS = Movement Disorder Society - Unified Parkinson's disease rating scale, LEDD = Levodopa 
equivalent daily dose, Receiving dopaminergic therapy = LEDD>0, GDS-15 = 15 item Geriatric Depression Scale , PSQI - Pittsburgh Sleep 
Quality Index global score , ESS = Epworth Sleepiness Scale , PDQ-39 = Parkinson’s Disease Questionnaire summary index.  
N = 15 did not complete the MoCA 
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Table 3. Clinical characteristics of newly diagnosed participants with Parkinson’s disease and differing severities of visual hallucinations experienced 
 Minor VHs 
(N=10) 
Simple VHs (N=9) Illusions (N=4) Complex VHs 
(N=11) 
X2  P 
Age (years) 66.7 ± 11.4 66.9 ± 9.0 69.1 ± 11.9 67.4 ± 5.5 2.2 0.537 
Sex: male n (%)  7 (70.0) 7 (77.8) 3 (75.0) 10 (90.9) 5.1 0.278x 
PD-MCI n (%) 6 (60.0) 4 (44.4) 2 (50.0) 4 (36.4) 1.7 0.797x 
Education (years) 11.3 ± 3.3 13.7 ± 3.7 11.0 ± 0.8 12.2 ± 4.2 2.7 0.448 
Disease duration (months) 4.8 ± 3.3 6.6 ± 7.4 7.9 ± 4.2 6.8 ± 2.1 3.7 0.291 
Motor phenotype n (%) 
PIGD 
Indeterminate 
Tremor Dominant 
 
9 (90.0) 
1 (10.0) 
0 (0.0) 
 
4 (44.4) 
2 (22.2) 
3 (33.3) 
 
2 (50.0) 
1 (25.0) 
1 (25.0) 
 
6 (54.5) 
1 (9.1) 
4 (36.4) 
11.2 0.191x 
MoCA 24.1 ± 4.1 23.4 ± 4.5 23.3 ± 2.1 24.0 ± 4.1 0.3 0.953 
MMSE 28.1 ± 1.5 28.3 ± 1.3 28.5 ± 1.0 28.1 ± 1.6 0.3 0.968 
MDS-UPDRS Part II 14.3 ± 6.2 10.2 ± 4.3 12.5 ± 5.9 12.2 ± 5.3 1.4 0.696 
MDS-UPDRS Part III 27.2 ± 12.2 26.8 ± 12.0 34.0 ± 11.0 28.4 ± 13.2 1.5 0.686 
Hoehn and Yahr 2.2 ± 0.8 1.8 ± 0.7 2.5 ± 0.6 1.8 ± 0.6 4.6 0.208 
LEDD (mg/day) 173.0 ± 74.5 206.7 ± 186.5 130.0 ± 124.9 204.1 ± 183.6 0.8 0.826 
GDS-15 4.2 ± 3.4 3.8 ± 4.1 4.5 ± 1.0 3.4 ± 2.7 1.8 0.610 
PSQI 6.9 ± 5.1 6.7 ± 5.4 7.3 ± 3.6 7.8 ± 4.6 0.7 0.883 
ESS 9.3 ± 6.7 7.8 ± 4.2 6.8 ± 3.7 9.8 ± 4.5 2.2 0.542 
PDQ-39 28.0 ± 18.6 23.7 ± 17.0 31.8 ± 18.3 26.1 ± 17.2 0.9 0.832 
Data presented as mean ± SD unless otherwise stated X= chi squared, t= independent samples t test, remainder of tests were Mann–Whitney U test. Post hoc Bonferroni correction for group comparison at p < 
0.008. 
PD-MCI = Mild cognitive impairment at 1.5 SD, PIGD = Postural Instability Gait Difficulty, MoCA = Montreal Cognitive Assessment, MMSE = Mini-Mental State Examination, MDS-UPDRS = Movement Disorder Society - 
Unified Parkinson's disease rating scale, LEDD = Levodopa equivalent daily dose, GDS-15 = 15 item Geriatric Depression Scale , PSQI - Pittsburgh Sleep Quality Index global score , ESS = Epworth Sleepiness Scale , 
PDQ-39 = Parkinson’s Disease Questionnaire summary index, VHs = visual hallucinations. Data presented as mean ± SD unless otherwise stated. N=4 did not complete the MoCA. 
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Table 2: Regression coefficients and model fit of predictors of MoCA, PDQ-39 and MDS-UPDRS part 
III scores. 
     95% CI for β 
  t p β Lower 
Bound 
Upper 
Bound 
MoCA Initial modela      
 Age -4.1 <0.001 -0.3 -0.2 -0.1 
 Education 3.0 0.003 0.2 0.1 0.4 
 Initial model + Recurrent VHsb -2.6 0.010 -0.2 -3.0 -0.4 
PDQ-39 Initial modelc      
 GDS-15 9.0 <0.001 0.5 2.3 3.6 
 MDS-UPDRS part III 4.5 <0.001 0.3 0.2 0.5 
 Age -3.6 <0.001 -0.2 -0.5 -0.1 
 Education -2.4 0.020 -0.1 -1.0 -0.1 
 Initial model + Recurrent VHsd 2.8 0.006 0.2 1.5 9.3 
MDS-UPDRS Part III Initial modele      
 GDS-15 3.5 0.001 0.3 0.6 2.0 
 PD-MCI 2.5 0.012 0.2 1.0 8.5 
 Initial model + Recurrent VHsf -0.1 0.906 0.0 -4.8 4.2 
a: R = 0.477, R2 = 0.227, adjusted R2 = 0.216, F = 20.0, p<0.001, SE = 3.2 
b: R = 0.514, R2 = 0.264, adjusted R2 = 0.248, F = 16.2, p<0.001, SE = 3.2, ΔR2 = 0.037 
c: R = 0.725, R2 = 0.526, adjusted R2 = 0.514, F = 41.4, p<0.001, SE = 10.0 
d: R = 0.741, R2 = 0.549, adjusted R2 = 0.534, F = 36.1, p<0.001, SE = 9.8, ΔR2 = 0.023 
e: R = 0.358, R2 = 0.128, adjusted R2 = 0.116, F = 11.1, p<0.001, SE = 11.4  
f: R = 0.358, R2 = 0.128, adjusted R2 = 0.111, F = 7.3, p<0.001, SE = 11.4, ΔR2 = 0.000  
CI = confidence intervals, MoCA = Montreal Cognitive Assessment, VHs = visual hallucinations, MDS-UPDRS = Movement Disorder Society - 
Unified Parkinson's disease rating scale, GDS-15 = 15 item Geriatric Depression Scale, PDQ-39 = Parkinson’s Disease Questionnaire 
summary index, PD-MCI = Mild Cognitive Impairment applying cut-off of 1.5SD below normative values, Significant results highlighted in 
bold. 
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Supplementary Table 3. Summary of visual hallucination classification 
Classification of Visual 
Hallucination 
Description 
Complex Hallucination Formed visual hallucination such as people, animals, objects, devils 
etc. 
Illusion A misperception in vision e.g. wallpaper patterns move, perceiving 
clothing as an animal or person. 
Simple Hallucination – 
without migraine 
Unformed visual hallucinations such as lights, spots, colours, 
shadows. 
Simple Hallucination –  
in context of migraine 
Unformed visual hallucinations as described above that occur 
during a migraine. 
Minor Hallucination - 
Presence 
The feeling of a person, being or thing nearby or out of view. 
Minor Hallucination - 
Passage 
The feeling or vision of an animal, shadow or person passing by. 
Floater Generally spots which move with the individual’s eyes. 
 
